Outcomes after URD SCT for ALL in CR1: univariate analysis
| Outcome event . | N . | Probability (95% CI) . |
|---|---|---|
| ANC more than 0.5 × 109/L | 162 | |
| at 28 d | 92 (88-96) | |
| at 100 d | 96 (93-99) | |
| Acute GVHD, grades II-IV at 100 d | 167 | 50 (43-58) |
| Acute GVHD, grades III-IV at 100 d | 167 | 25 (19-32) |
| Chronic GVHD | 165 | |
| at 1 y | 38 (31-46) | |
| at 3 y | 43 (35-51) | |
| at 5 y | 43 (35-51) | |
| Treatment-related mortality | 166 | |
| at 100 d | 24 (18-31) | |
| at 1 y | 36 (29-43) | |
| at 3 y | 41 (33-49) | |
| at 5 y | 42 (34-50) | |
| Relapse | 166 | |
| at 1 y | 15 (10-21) | |
| at 3 y | 20 (14-26) | |
| at 5 y | 20 (14-26) | |
| Disease-free survival | 166 | |
| at 1 y | 49 (41-57) | |
| at 3 y | 39 (32-47) | |
| at 5 y | 38 (31-46) | |
| Overall survival | 169 | |
| at 1 y | 52 (45-60) | |
| at 3 y | 41 (33-49) | |
| at 5 y | 39 (31-47) |
| Outcome event . | N . | Probability (95% CI) . |
|---|---|---|
| ANC more than 0.5 × 109/L | 162 | |
| at 28 d | 92 (88-96) | |
| at 100 d | 96 (93-99) | |
| Acute GVHD, grades II-IV at 100 d | 167 | 50 (43-58) |
| Acute GVHD, grades III-IV at 100 d | 167 | 25 (19-32) |
| Chronic GVHD | 165 | |
| at 1 y | 38 (31-46) | |
| at 3 y | 43 (35-51) | |
| at 5 y | 43 (35-51) | |
| Treatment-related mortality | 166 | |
| at 100 d | 24 (18-31) | |
| at 1 y | 36 (29-43) | |
| at 3 y | 41 (33-49) | |
| at 5 y | 42 (34-50) | |
| Relapse | 166 | |
| at 1 y | 15 (10-21) | |
| at 3 y | 20 (14-26) | |
| at 5 y | 20 (14-26) | |
| Disease-free survival | 166 | |
| at 1 y | 49 (41-57) | |
| at 3 y | 39 (32-47) | |
| at 5 y | 38 (31-46) | |
| Overall survival | 169 | |
| at 1 y | 52 (45-60) | |
| at 3 y | 41 (33-49) | |
| at 5 y | 39 (31-47) |
Probabilities of ANC less than 0.5 × 109/L, acute GVHD, chronic GVHD, treatment-related mortality, and relapse were calculated using the cumulative incidence estimate. Disease-free survival and overall survival were calculated using the Kaplan-Meier product limit estimate.
GVHD indicates graft-versus-host disease.